Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 369

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 369
---

Warrants for consideration equal to the Black-Scholes value thereof, which shall be settled, at the option of the Company in either (i)
the form of rights convertible into the consideration receivable by holders of the underlying shares of common stock, based upon the value
of the shares of the successor entity over a specified period or (ii) cash in an amount equal to the Black-Scholes value.

The Company’s Series
A Common Warrants are exercisable into Common Stock and are recorded as equity.

September 2024 Series C Common Warrants (Successor)

The Company’s
September 2024 Series C Common Warrants were initially exercisable for cash at an initial exercise price equal to $ (as adjusted
for stock splits, stock dividends, stock combinations, recapitalizations and similar events). The exercise price is also subject to adjustment
for the sale of Common Stock, or issuance or modification of options to result in the purchase of share of Common Stock at an effective
price per share lower than the then current Series C Common Warrant exercise price. Additionally, should the Company issue any variable
priced convertible securities, the holders may elect an alternative exercise price that allows exercise at the effective purchase price
applicable to the convertible security.

The September 2024 Series
C Common Warrants are exercisable beginning six months after the issuance date (the “Initial Exercisability Date”) and expire
on the third anniversary of the Initial Exercisability Date. The Series C Common Warrants require “buy-in” payments to be
made by us for failure to deliver any shares of Common Stock issuable upon exercise.

If at the time of exercise
of the Series C Common Warrants, there is no effective registration statement registering the shares of the Common Stock underlying the
Series C Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

If we issue options, convertible
securities, warrants, shares, or similar securities to holders of Common Stock, each holder of Series C Common Warrants has the right
to acquire the same as if the holder had exercised its Series C Common Warrants. The holders of Series C Common Warrants are entitled
to receive any dividends paid or distributions made to our holders of Common Stock on an “as if converted” basis.

The Series C Common Warrants
prohibit us from entering into specified fundamental transactions unless the successor entity assumes all of our obligations under the
Series C Common Warrants under a written agreement before the